Refine
Year of publication
Document Type
- Preprint (668)
- Article (371)
- Conference Proceeding (1)
- Working Paper (1)
Language
- English (1041)
Has Fulltext
- yes (1041)
Is part of the Bibliography
- no (1041)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
Institute
- Physik (1034)
- Frankfurt Institute for Advanced Studies (FIAS) (958)
- Informatik (924)
- Informatik und Mathematik (3)
- Medizin (3)
- Geowissenschaften (2)
- Hochschulrechenzentrum (2)
- Wirtschaftswissenschaften (2)
- Biochemie und Chemie (1)
- Center for Financial Studies (CFS) (1)
Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and treat HIV-1 infection. However, viral escape through mutation of the HIV-1 envelope glycoprotein (Env) limits clinical applications. Here we describe 1-18, a new VH1-46-encoded CD4 binding site (CD4bs) bNAb with outstanding breadth (97%) and potency (GeoMean IC50 = 0.048 μg/mL). Notably, 1-18 is not susceptible to typical CD4bs escape mutations and effectively overcomes HIV-1 resistance to other CD4bs bNAbs. Moreover, mutational antigenic profiling uncovered restricted pathways of HIV-1 escape. Of most promise for therapeutic use, even 1-18 alone fully suppressed viremia in HIV-1-infected humanized mice without selecting for resistant viral variants. A 2.5-Å cryo-EM structure of a 1-18-BG505SOSIP.664 Env complex revealed that these characteristics are likely facilitated by a heavy-chain insertion and increased inter-protomer contacts. The ability of 1-18 to effectively restrict HIV-1 escape pathways provides a new option to successfully prevent and treat HIV-1 infection.